Testing and evaluation of antimalarial drug quality in Dien Bien, Quang Tri, Dak Lak and Binh Phuoc in 2004

Antimalarial drug samples were collected from different parts of the country for quality investigation in 2004. A total of 129 samples of different batches were collected at three rounds and cross-checked at local, central level and abroad. At the round one, three out of 49 collected samples were found substandard. One of 40 samples of the second round was determined counterfeit (2.5%). The re-analysis of 51 samples at NIDQC revealed two from the first round were substandard and one from the second round was counterfeit

Pharmacokinetics of the antimalarial combination CV8 when given in the manner of a therapeutic dosage regimen in healthy male subjects

The study was conducted in 2002 for analysis by non-linear regression of compartmental pharmacokinetic model. The results: the plasma-concentration of piperaquine at day 1 and day 3 after CV8 administration were determined. At first stage, only the basic parameters derived from non-compartmental methods were presented and another parameters, models is expected to be presented in later stages. The plasma-concentration of piperaquine of all volunteers were determined with Cmax on day 1 was 1015 nM/L, on day 2 was 1050 nM/L, T1/2 was 30-57 days and Tmax of piperaquine was 3-5 hours after using

Primary control on quality of tablet and injection forms of artesunate by high performance liquid chromatography (HPLC)

The Micheal Ashton's modified method was used to determinate artesunate (AS) concentrations in tablets and injection forms in order to improve the skillfulness of laboratory staff of National Institute of Malariology - Parasitology - Entomology. Average contents of artesunate of the tablets and injection form of the samples collected in 2001 and 2002 which met the stipulated criteria of Ministry of Health. Tablet content in 2001 was 48.09mg/tablet and in 2002 was 48.40mg/tablet. Injection content in 2001 was 60.50mg/vial and 56.09mg/vial in 2003